Answers are grounded in this paper and cite their sources.
MYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression.
No takes yet. Share an insight, caveat, or question.
Bishop et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: